|
Virtual Meetings 2020
Meet The Professor: Immunotherapy and Novel Agents in Gynecologic CancersFor more information, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153. PARTICIPATING FACULTY
Deborah K Armstrong, MD Professor of Oncology Professor of Gynecology and Obstetrics Skip Viragh Outpatient Cancer Building Johns Hopkins Sidney Kimmel Comprehensive Cancer Center Baltimore, Maryland Michael J Birrer, MD, PhD Vice Chancellor, UAMS Director, Winthrop P Rockefeller Cancer Institute Director, Cancer Service Line University of Arkansas for Medical Sciences Little Rock, Arkansas Robert L Coleman, MD Chief Scientific Officer US Oncology Research Gynecologic Oncology The Woodlands, Texas Martee L Hensley, MD, MSc Attending Physician, Gynecologic Medical Oncology Memorial Sloan Kettering Cancer Center Professor of Medicine Weill Cornell Medical College New York, New York Gottfried E Konecny, MD Professor-in-Residence Division of Hematology-Oncology Department of Medicine David Geffen School of Medicine UCLA Medical Center Los Angeles, California Joyce F Liu, MD, MPH Associate Chief and Director of Clinical Research Division of Gynecologic Oncology Dana-Farber Cancer Institute Boston, Massachusetts Bradley J Monk, MD Professor, Division of Gynecologic Oncology Arizona Oncology (US Oncology Network) University of Arizona College of Medicine Creighton University School of Medicine at St Joseph’s Hospital Medical Director, US Oncology Network (McKesson) Gynecologic Program Co-Director, GOG Partners Member, Board of Directors, GOG Foundation Phoenix, Arizona Ana Oaknin, MD, PhD Head of Gynaecologic Cancer Programme Vall d'Hebron Institute of Oncology Hospital Universitari Vall d’Hebron Vall d’Hebron Barcelona Hospital Campus Barcelona, Spain David M O'Malley, MD Professor Division Director, Gynecologic Oncology Co-Director Gynecologic Oncology Phase I Program The Ohio State University and The James Cancer Center Columbus, Ohio Richard T Penson, MD, MRCP Associate Professor of Medicine Harvard Medical School Clinical Director, Medical Gynecologic Oncology Massachusetts General Hospital Boston, Massachusetts Matthew A Powell, MD Professor and Chief Division of Gynecologic Oncology Washington University School of Medicine St Louis, Missouri Brian M Slomovitz, MD Professor, OB-GYN, Florida International University Director, Gynecologic Oncology Co-Chair, Cancer Research Committee Mount Sinai Medical Center Miami, Florida Krishnansu S Tewari, MD Professor and Division Director Division of Gynecologic Oncology University of California, Irvine Irvine, California Professor Ignace Vergote Chairman, Department of Obstetrics and Gynaecology Gynaecological Oncologist Leuven Cancer Institute University Hospital Leuven Leuven, Belgium Shannon N Westin, MD, MPH Associate Professor Director, Early Drug Development Department of Gynecologic Oncology and Reproductive Medicine The University of Texas MD Anderson Cancer Center Houston, Texas SERIES MODERATOR Neil Love, MD Research To Practice Agenda
Module 1: Anti-PD-1/PD-L1 Monotherapy for Metastatic Endometrial Cancer Module 2: Immune Checkpoint Inhibitors in Combination with Other Systemic Therapies for Metastatic Endometrial Cancer Module 3: Current Indications for and Future Role of Anti-PD-1/PD-L1 Antibodies in Cervical Cancer Module 4: Investigative Approaches with Immune Checkpoint Inhibitors for Ovarian Cancer Module 5: Other Novel Agents and Strategies in Gynecologic Cancers
Target Audience
CME Credit Form American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC) Content Validation and Disclosures Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. FACULTY — Dr Konecny has no relevant conflicts of interest to disclose. The following faculty reported relevant financial relationships with ineligible entities: Dr Armstrong — Advisory Committee: AbbVie Inc, Cue Biopharma, Eisai Inc; Contracted Research: AstraZeneca Pharmaceuticals LP, Clovis Oncology, Eisai Inc, Pfizer Inc, Syndax Pharmaceuticals Inc; Data and Safety Monitoring Board/Committee: AstraZeneca Pharmaceuticals LP. Dr Birrer — Advisory Committee: AstraZeneca Pharmaceuticals LP, Clovis Oncology, Tesaro, A GSK Company; Data and Safety Monitoring Board/Committee: VBL Therapeutics. Dr Coleman — Advisory Committee and Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Clovis Oncology, Genentech, a member of the Roche Group, GlaxoSmithKline, ImmunoGen Inc, Janssen Biotech Inc, Merck, Novocure, Roche Laboratories Inc, Takeda Pharmaceuticals USA Inc, Tesaro, A GSK Company; Contracted Research: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Clovis Oncology, Genentech, a member of the Roche Group, Janssen Biotech Inc, Merck, Roche Laboratories Inc; Data and Safety Monitoring Board/Committee: AstraZeneca Pharmaceuticals LP, VBL Therapeutics. Dr Hensley — Consulting Agreements: Exact Sciences Inc, Lilly; Data and Safety Monitoring Board/Committee: Dana-Farber/Harvard Cancer Center; Spouse Employment: Sanofi Genzyme; Strategic Advisory Board: GlaxoSmithKline. Dr Liu — Advisory Committee: AstraZeneca Pharmaceuticals LP, Eisai Inc, Epsila Bio, Genentech, a member of the Roche Group, GlaxoSmithKline, Regeneron Pharmaceuticals Inc; Consulting Agreement: Genentech, a member of the Roche Group. Dr Monk — Consulting Agreements: Agenus Inc, Akeso Inc, Aravive Inc, AstraZeneca Pharmaceuticals LP, Clovis Oncology, Eisai Inc, Elevar Therapeutics, Genentech, a member of the Roche Group, Genmab, GOG Foundation Inc, Gradalis Inc, ImmunoGen Inc, Iovance Biotherapeutics, Karyopharm Therapeutics, McKesson/US Oncology Network, Merck, Mersana Therapeutics, Myriad Genetic Laboratories Inc, Novocure Inc, Pfizer Inc, Puma Biotechnology Inc, Seagen Inc, Sorrento Therapeutics, Tesaro, A GSK Company, VBL Therapeutics; Speakers Bureau: AstraZeneca Pharmaceuticals LP, Clovis Oncology, Eisai Inc, Genentech, a member of the Roche Group, Merck, Tesaro, A GSK Company. Dr Oaknin — Advisory Committee: AstraZeneca Pharmaceuticals LP, Clovis Oncology, Genmab, ImmunoGen Inc, PharmaMar, Roche Laboratories Inc, Tesaro, A GSK Company; Paid Travel: AstraZeneca Pharmaceuticals LP, PharmaMar, Roche Laboratories Inc. Dr O'Malley — Advisory Committee and Consulting Agreements (Personal Fees): AbbVie Inc, Agenus Inc, Ambry Genetics, Amgen Inc, AstraZeneca Pharmaceuticals LP, Clovis Oncology, Eisai Inc, Elevar Therapeutics, Genentech, a member of the Roche Group, GOG Foundation Inc, ImmunoGen Inc, Iovance Biotherapeutics, Janssen Biotech Inc, Johnson & Johnson Pharmaceuticals, Merck, Mersana Therapeutics, Myriad Genetic Laboratories Inc, Novartis, Novocure Inc, Regeneron Pharmaceuticals Inc, Rubius Therapeutics, Seagen Inc, Tarveda Therapeutics, Tesaro, A GSK Company; Contracted Research (Personal Fees): Clovis Oncology, Mersana Therapeutics; Contracted Research (to Institution): AbbVie Inc, Agenus Inc, Ajinomoto Co Inc, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Daré Bioscience, Eisai Inc, EMD Serono Inc, Ergomed Plc, Genentech, a member of the Roche Group, Genmab, GOG Foundation Inc, ImmunoGen Inc, Iovance Biotherapeutics, Janssen Biotech Inc, Johnson & Johnson Pharmaceuticals, Ludwig Institute for Cancer Research Ltd, Merck, National Cancer Institute, New Mexico Cancer Care Alliance, Novocure Inc, PRA Health Sciences, Regeneron Pharmaceuticals Inc, Seagen Inc, Stemcentrx, Syneos Health, Tesaro, A GSK Company, TRACON Pharmaceuticals Inc, VentiRx Pharmaceuticals Inc, Yale University; Data and Safety Monitoring Board/Committee: Watermark Research Partners Inc. Dr Penson — Advisory Committee: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Care4ward (unpaid), Clovis Oncology, Curio Science, Eisai Inc, Genentech, a member of the Roche Group, Janssen Biotech Inc, Johnson & Johnson Pharmaceuticals, Merck, Mersana Therapeutics, NewLink Genetics, Nexus Group Global, Pieris Pharmaceuticals Inc, Roche Laboratories Inc, Sutro Biopharma, Syndax Pharmaceuticals Inc, Tesaro, A GSK Company, Vascular Biogenics; Contracted Research: Array BioPharma Inc, a subsidiary of Pfizer Inc, AstraZeneca Pharmaceuticals LP, Eisai Inc, Genentech, a member of the Roche Group, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Tesaro, A GSK Company, Vascular Biogenics; Data and Safety Monitoring Board/Committee: AbbVie Inc, AstraZeneca Pharmaceuticals LP. Dr Powell — Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Clovis Oncology, Eisai Inc, Genentech, a member of the Roche Group, GlaxoSmithKline, Merck, Tesaro, A GSK Company. Dr Slomovitz — Advisory Committee: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Clovis Oncology, Eisai Inc, Genentech, a member of the Roche Group, GlaxoSmithKline, Merck, Myriad Genetic Laboratories Inc; Consulting Agreement: GOG Foundation Inc. Dr Tewari — Advisory Committee: AbbVie Inc, Amgen Inc, AstraZeneca Pharmaceuticals LP, Clovis Oncology, Eisai Inc, Genentech, a member of the Roche Group, Merck, Tesaro, A GSK Company; Contracted Research (to Institution): Regeneron Pharmaceuticals Inc; Data and Safety Monitoring Board/Committee: Iovance Biotherapeutics; Speakers Bureau: AstraZeneca Pharmaceuticals LP, Clovis Oncology, Eisai Inc, Merck, Tesaro, A GSK Company. Prof Vergote — Advisory Committee: Amgen (Europe) GmbH, AstraZeneca Belux, Carrick Therapeutics, Clovis Oncology, Debiopharm Group, Deciphera Pharmaceuticals Inc, Doctaforum Servicios Sl, F Hoffmann-La Roche Ltd, Genmab, GlaxoSmithKline, ImmunoGen Inc, MSD Belgium, OCTIMET Oncology NV, Oncoinvent AS, PharmaMar, Roche Laboratories Inc, SOTIO as, Takeda Pharmaceuticals USA Inc, Tesaro, A GSK Company, Verastem Inc; Consulting Agreements: AstraZeneca Pharmaceuticals LP, Roche Laboratories Inc; Contracted Research: Amgen Inc, Genmab, Oncoinvent AS, Roche Laboratories Inc; Paid Travel: Amgen Inc, AstraZeneca Pharmaceuticals LP, GlaxoSmithKline, Merck, Roche Laboratories Inc. Dr Westin — Consulting Agreements: Agenus Inc, AstraZeneca Pharmaceuticals LP, Clovis Oncology, Eisai Inc, EQRx, Genentech, a member of the Roche Group, GlaxoSmithKline, Lilly, Merck, Mereo BioPharma, Novartis, Zentalis Pharmaceuticals; Contracted Research: AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Clovis Oncology, Cotinga Pharmaceuticals, Genentech, a member of the Roche Group, GlaxoSmithKline, Mereo BioPharma, Novartis, OncXerna Therapeutics Inc, Zentalis Pharmaceuticals. SERIES MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, Daiichi Sankyo Inc, Eisai Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Natera Inc, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Servier Pharmaceuticals LLC, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc and Zymeworks Inc. RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.Commercial Support These activities are supported by educational grants from Eisai Inc, Genmab and Seagen Inc, Merck, and Tesaro, A GSK Company. |